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This descriptive study investigates in a rabbit model of atherosclerosis (i) the extent of atherogenesis induced by cyclosporine
A (CsA) or hyperlipidemia alone or in combination and (ii) whether thymoquinone (TQ), a known herbal antioxidant, oﬀers
protection against these eﬀects. New Zealand White female rabbits were assigned to ﬁve groups of six animals each: Group I,
control; Group II, CsA [25mgkg−1 day−1 orally (PO)]; Group III, 1% cholesterol; Group IV, 1% cholesterol + CsA (25mgkg−1
day−1 PO); and Group V, 1% cholesterol + CsA (25mgkg−1 day−1 PO) + TQ (10mgkg−1 day−1 PO). Lipids and oxidative stress
parameters [Malondialdehyde (MDA) and protein carbonyl] and aortic atherosclerosis were compared. CsA alone did not show a
signiﬁcanteﬀectoneitherserumlipidsanddidnotinduceatherosclerosis.High-cholesteroldietinducedatherosclerosis(45 ±11%
of the intimal surface of aorta was covered with atherosclerotic plaques). CsA and high-cholesterol diet increased atherosclerosis
severity as measured from intimal and media lesions, but did not aﬀect the extent of atherosclerosis. TQ decreased aortic MDA
by 83%. It was also associated with reduced aortic atherosclerosis extend by 52% compared with Group IV. We concluded that (i)
CsA aggravates hyperlipidemia-induced atherosclerosis and (ii) TQ attenuates the oxidative stress and atherogenesis induced by
the combined eﬀect of CsA and hyperlipidemia.
1.Introduction
Patients receiving calcineurin inhibitors such as cyclosporine
A (CsA) including transplant patients and those with
immune-mediated kidney diseases are usually hyperlipemic.
Both of hyperlipidemia and CsA contribute to the increased
cardiovascular burden in humans and animal models [1–
3]. Therefore, the relative contribution of CsA versus hyper-
lipidemia alone or in combination to the cardiovascular
disease burden is diﬃcult to dissect in humans. Adding
to this complexity is the fact that both hyperlipidemia
and CsA causes tissue injury by increasing the oxidative
stress. Furthermore, the eﬀect of CsA on atherosclerosis is
complex. On one hand, CsA inhibits T-cell function and
thereby recruitment of inﬂammatory cells needed to initiate
atherosclerosis [4], which depends on T-cell activation. On
theotherhand,CsAhasbeendemonstratedtosynergistically
exacerbate the vasoconstrictive eﬀects of oxidized low-
densitylipoprotein[5,6]andthusaggravatesatherosclerosis.
To determine the relative contribution of CsA and
hyperlipidemia to induce atherosclerosis, we reasoned that
high cholesterol-fed rabbits are a good model to study.
First, rabbits have been used reliably to induce an atheroma
model with intact endothelium, which resembles human
atherosclerosis [7, 8]. Secondly, oxidative stress has been
linked to tissue injury by hyperlipidemia [9, 10]. And thirdly,
wehavedemonstratedthatthymoquinone(TQ),whichisthe
bioactive constituent of the volatile oil of Nigella sativa seeds,
protects against hyperlipidemia-induced atherosclerosis in
rabbits. This eﬀect is likely due to attenuation of oxidative
stress [11, 12].
We therefore, wished to test the hypothesis that CsA
aggravates hyperlipidemia-induced atherosclerosis by syn-
ergistically enhancing the reactive oxygen species (ROS)2 Evidence-Based Complementary and Alternative Medicine
Table 1: Experimental groups.
Group Diet and drug regimen
I( n = 6) Control; regular diet for 8 weeks
II (n = 6) CsA; CsA [25mgkg−1 day−1 orally (PO)]
III (n = 6) Cholesterol; 1% cholesterol diet for 8 weeks
IV (n = 6) Cholesterol + CsA; 1% cholesterol + CsA
(25mgkg−1 day−1 PO)
V( n = 6) Cholesterol + CsA + TQ; 1% cholesterol + CsA
(25mgkg−1 day−1 PO) + TQ (10mgkg−1 day−1 PO)
n = number.
activity and that TQ ameliorates these eﬀects. In this study,
we aimed to describe these eﬀects.
2. Methods
2.1. Drugs. The drugs used were CsA A (CsA):Neoral oral
solution (100mgml−1) (Novartis Pharmaceuticals Canada
Inc., Dorval, QC, Canada) and TQ: 2-isopropyl-5-methyl-
1,4-benzoquinone (Sigma-Aldrich, St. Louis, MO, USA)
dissolved in pure corn oil (Sigma-Aldrich, St Louis, MO
63103, USA) to give a concentration of 75mgml−1.
2.2. Animals and Experimental Design. Thirty female New
Zealand White rabbits, weighing 1.8–2kg and aged 6–8
weeks, were assigned to ﬁve groups of six animals each
(Table 1). After 1 week of adaptation on regular diet. The
rabbits were assigned to the following groups: Group I,
control; Group II, CsA (25mgkg−1 day−1 per 8 weeks PO);
Group III, 1% cholesterol; Group IV, 1% cholesterol + CsA
(25mgkg−1 day−1 per 8 weeks PO); and Group V, 1%
c h o l e s t e r o l+C s A( 2 5 m g k g −1 day−1 8 weeks PO) + TQ
(10mgkg−1 day−1 per 8 weeks PO). The diet was prepared
by Purina (St Louis, MO, USA) and did not contain any
antioxidants. Drugs were given orally through nasogastric
tubes (water was given ad libitum). The rabbits were housed
in individual cages at room temperature of 22–24◦Ca n da
relative humidity of 40–60% under a 12-h light/12-h dark
cycle. The experimental protocols were approved by the
Ethics Committee of the University of Saskatchewan and the
animal care was performed according to the approved stan-
dards for Laboratory Animal Care. Following 18 h of fasting,
blood samples (from the ear marginal artery) were collected
before (0 time) and after 4 and 8 weeks on the respective
diets for measurement of total cholesterol (TC), triglycerides
(TG), low density lipoprotein-cholesterol (LDL-C), high
density lipoprotein-cholesterol (HDL-C), TC/HDL-C and
serum malondialdehyde (MDA). Serum protein carbonyl
was measured at week 8 only. At the end of the protocol (8
weeks) rabbits were anesthetized with ethanol, pentobarbital
sodium (50mgkg−1 IV) (Bimeda-MTC Animal Health Inc.,
Cambridge,ON,Canada)inthemarginalearveinandaortas
were removed for the assessment of aortic MDA and protein
carbonyl and atherosclerotic changes.
2.3. Serum Lipids. TC, TG and HDL-C were measured on
an automated Beckman Synchron LX20 Clinical System
Analyzer. LDL-C was calculated. Cholesterol risk ratio was
estimated using the TC/HDL-C ratio.
2.4. Preparation of the Aortic Tissue for Measurement of MDA
and Protein Carbonyl. T h ea o r t i cr i n g sw e r ec u ta tt h er o o t s
of the aortic arches and kept in buﬀered 10% formalin
for histological examination using our previously described
methods [9, 13].
Aortas between the origin and bifurcation to iliac arteries
were removed, cleaned of gross adventitial tissue and cut
longitudinally into two halves. One half was used for the
assessment of atherosclerotic changes, and the other half
was kept on ice for preparation of the supernatants, by a
previously described method [14], for measurement of the
aortic tissue MDA and protein carbonyl.
2.5. Serum and Aortic MDA (Thiobarbituric Acid-Reactive
Substances). MDA levels in the aortic tissue supernatant
and serum were measured as thiobarbituric acid-reactive
substances (TBARs) by the previously described method
[14, 15]. The MDA content of the tissue was expressed as
nmolmg−1 proteins and that of serum as nmolml−1.
2.6. Serum Protein Carbonyl. The protein carbonyl levels
in the serum were measured using a Cayman Chemical
Carbonyl Protein Assay Kit (Cayman Chemical Company,
Ann Arbor, Michigan, USA). The absorbance was measured
at a wavelength between 360 and 386nm using an ELx
808TM Absorbance microplate reader (BioTek Instruments,
Inc. Highland Park, Vermont, USA). The protein carbonyl
content of the tissue was expressed as nmolmg−1 proteins
and that of serum as nmolml−1.
2.7. Tissue Protein Measurement. The protein content of was
determinedusingaModiﬁedLowryProteinAssayKit(Pierce
Biotechnology, Rockford, IL, USA). The absorbance was
measured at a wavelength of 750nm using an ELx 808TM
Absorbance microplate reader (BioTek Instruments, Inc.,
Highland Park, Vermont, USA).
2.8. Assessment of Atherosclerotic Changes in the Aorta. The
sixanimalsfromeachgroupwereassessedforatherosclerotic
changes using Herxheimer’s solution containing Sudan IV
for lipid staining [9, 16]. Photographs of the stained intimal
surface of the aorta were taken with a digital camera. The
total and atherosclerotic areas of the intimal surface of
the aorta were measured by using image analysis software
Scion Image for Windows (Scion Corporation, Frederick,
MD USA). The extent of atherosclerosis was expressed as a
percentage of total intimal surface area.
2.9. Quantiﬁcation and Histological Assessment of Atheroscle-
rotic Lesions in the Aortic Rings. All methods are well estab-
lished at our laboratory [9]. The aortic rings specimens were
cut across and embedded in paraﬃn. The histopathological
ﬁndings were evaluated by a blinded pathologist.Evidence-Based Complementary and Alternative Medicine 3
H&E, Verhoeﬀ’s elastic stained sections were used
for microscopic morphometric evaluation using the Scion
software program. For these experiments, data have been
reported as the mean intimal area, determined by six
experimental measurements [17]. Video microscopy was
usedtooutlinetheendothelium,internalelasticlamina(IEL)
and external elastic lamina (EEL). Then, area measurements
were calculated using an image software program (Scion,
Frederick, MD). Intima area (between the endothelium and
IEL) and media area (between the IEL and EEL) were
measured for each aorta and averaged for each group.
The total cross-sectional intimal area was measured
between the endothelial cell monolayer and the internal
elastic lamina (IEL) and the total cross-sectional medial area
was measured between the external elastic lamina (EEL)
and the IEL as documented by previous methods [18]. The
intimal and medial surface areas as well as the intima/media
ratio were taken as measures of the severity of atherosclerosis
[18].
2.10. Statistical Analysis. Results are expressed as mean ±
SD. Repeated-measures analysis of variance was used for
statistical analysis. A value of P < .05 was considered
signiﬁcant.
3. Results
3.1. Body Weight. There was a progressive increase in the
body weight of all groups. No signiﬁcant diﬀerences were
observed between the groups throughout the study period
(data not shown).
3.2. Serum Lipids. The basal levels of serum TC in Groups
I, II, III, IV and V were 1.38 ± 0.2, 1.35 ± 0.3, 1.26 ± 0.18,
1.35 ± 0.3 and 1.42 ± 0.4mmoll−1, respectively. The basal
levels were not signiﬁcantly diﬀerent among the groups. The
sequential changes in serum TC in the ﬁve groups are shown
in Figure 1. The serum levels of TC remained unchanged in
Groups I and II while they were elevated in Groups III, IV
and V as compared to their basal levels. The levels at week
8w e r en o td i ﬀerent from those at week 4 in all groups. In
Group V, TC was signiﬁcantly lower than that for Groups III
a n dI Va tw e e k8 .
The initial levels of serum TG in Groups I, II, III, IV and
Vw e r e0 . 7 9± 0.2, 0.94 ± 0.5, 1.02 ± 0.3, 0.74 ± 0.3 and
0.85 ± 0.2mmoll−1, respectively. These initial levels were
not signiﬁcantly diﬀerent among the groups. The sequential
changesinserumTGintheﬁvegroupsareshowninFigure 1.
The serum levels of TG remained unchanged in Groups I
and II while they were elevated in Groups III, IV and V as
comparedtotheirbasallevels.Nosigniﬁcantdiﬀerenceswere
found between the ﬁve groups at 4 and 8 weeks.
The basal levels of serum LDL-C in Groups I, II, III,
IV and V were 0.4 ± 0.2, 0.49 ± 0.2, 0.35 ± 0.2, 0.43 ±
0.1 and 0.51 ± 0.4mmoll−1, respectively. These levels were
not signiﬁcantly diﬀerent from each other. The sequential
changes in LDL-C in the ﬁve groups are shown in Figure 1.
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Figure 1: Sequential changes in serum TC and TG in the ﬁve
groups. Results are expressed as mean ± SD. aP < .05, 0 time versus
4 and 8 weeks in the respective groups. bP < .05, Group I versus
other groups. cP < . 0 5 ,G r o u pI Iv e r s u sG r o u pI I I ,I Vo rV .dP < .05,
Group III versus Group IV or V. eP < .05, Group IV versus Group V.
II while they were elevated in Groups III, IV and V compared
with their basal levels. No signiﬁcant diﬀerences were found
between the ﬁve groups at 4 and 8 weeks.
The initial levels of serum HDL-C in Groups I, II, III,
IV and V were 0.62 ± 0.2, 0.51 ± 0.4, 0.44 ± 0.2, 0.58 ± 0.1
and0.52±0.1mmoll−1,respectively.Again,theselevelswere
not signiﬁcantly diﬀerent among the groups. The sequential
changes in HDL-C in the ﬁve groups are shown in Figure 1.
SerumlevelsofHDL-CremainedunchangedinGroupsIand
II while they were elevated in Groups III, IV and V compared
to their basal levels. In Group V, HDL-C was signiﬁcantly
lower than that in Groups III and IV at both 4 and 8 weeks.
The basal values of TC/HDL-C ratios in Groups I, II,
III, IV and V were 2.31 ± 0.4, 2.64 ± 0.8, 3.04 ± 1, 2.35
± 0.3 and 2.75 ± 0.5, respectively. The basal values were
not signiﬁcantly diﬀerent among the groups. The sequential4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Sequential changes in serum LDL-C and HDL-C in the
ﬁve groups. Results are expressed as mean ± SD. aP < .05, 0 time
versus 4 and 8 weeks in the respective groups. bP < .05, Group I
versus other groups. cP < .05, Group II versus Group III, IV or V.
dP < .05, Group III versus Group IV or V. eP < .05, Group IV versus
Group V.
changes in these ratios in the ﬁve groups are shown in
Figure 2. The ratios remained unchanged in Groups I and
II and increased in Groups III, IV and V with respect to zero
time. The risk ratio values were increased in Groups III, IV
and V as compared to those in Groups I and II at 4 and 8
weeks. There were no signiﬁcant diﬀerences between Groups
III, IV and V at 8 weeks.
3.3. MDA Levels
3.3.1. Serum MDA. The basal values of serum MDA in
GroupsI–Vwere0.93 ±0.4,1.08 ±0.5,0.84 ±0.3,0.86 ±0.2
and 0.79 ± 0.2nmoll−1, respectively. The sequential changes
in serum MDA in the ﬁve groups are shown in Figure 2.T h e
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Figure 3: Sequential changes in TC/HDL-C ratio and serum MDA
in the ﬁve groups. Results are expressed as mean ± SD. aP < .05, 0
time versus 4 and 8 weeks in the respective groups. bP < .05, Group
I versus other groups. cP < .05, Group II versus Group III, IV or V.
dP < .05, Group III versus Group IV or V. eP < .05, Group IV versus
Group V.
values remained unchanged in Group I but increased in the
otherGr oupsat4and8weekswithrespecttobaselinevalues.
TheincreasesinMDAlevelsinGroupsIIIandVweresimilar.
MDA levels were the highest in Group IV at 4 and 8 weeks.
3.3.2. Aortic Tissue MDA. The MDA contents of the aorta in
theﬁvegroupsareshowninTable 2.I nG r oup1itwas0.25±
0.06nmolmg−1 protein.InGroupsIIandIII,theMDAlevels
were similar but lower than that in Group IV. Respectively
MDA levels in Groups II, III and IV were 2.1-, 2.2- and 7.3-
folds, respectively, higher as compared with Group I. The
MDA level in Group V was 83% lower than that in Group III
compared to Group IV, while it was similar to that in Group
I.Evidence-Based Complementary and Alternative Medicine 5
Table 2: Aortic atherosclerotic changes and MDA and serum protein carbonyl levels in the ﬁve groups at 8 weeks.
Group I Group II Group III Group IV Group V
Control CsA Cholesterol Cholesterol + CsA Cholesterol + CsA + TQ
Atherosclerosis 0 0 45.08 ± 11.65∗ 38.25 ± 8.74∗† 18.41 ± 2.38∗‡§
(% of total intimal surface)
Intimal area (×103 μm2)7 . 5 8 ± 1.52 4.72 ± 0.752 32.38 ± 7.13∗ 58.48 ± 15.51∗‡ 14.82 ± 1.87∗‡§
Medial area (×103 μm2) 52.31 ± 9.71 58.113 ± 8.89 64.56 ± 10.88 88.32 ± 10.08∗‡ 82.42 ± 4.71‡
Intima/media ratio 0.15 ± 0.01 0.08 ± 0.02 0.52 ± 0.06∗ 0.65 ± 0.12∗‡ 0.18 ± 0.03∗‡§
Aorta MDA (nmolmg−1)0 . 2 5 ± 0.06 0.47 ± 0.26∗ 0.53 ± 0.32∗ 1.83 ± 0.68∗†‡ 0.30 ± 0.03†‡§
Serum protein carbonyl content 1.34 ± 0.25 7.88 ± 1.88∗ 5.34 ± 1.36∗ 15.37 ± 1.29∗†‡ 9.50 ± 1.74∗†‡§
(nmolml−1)
R e s u l t sa r ee x p r e s s e da sm e a n± SD. Intimal and medial surface areas are expressed as ×103 μm2.
∗P < .05, Group I versus other groups.
†P < .05, Group II versus Groups III, IV and V.
‡P < .05, Group III versus Groups IV and V.
§P < .05, Group IV versus Group V.
Group I
(a)
Group II
(b)
Group III
(c)
Group IV
(d)
Group V
(e)
Figure 4: Representative photographs of the intimal surfaces of
aortas from the ﬁve experimental groups showing Sudan IV-stained
lipid deposits. The brick-red lipid deposits in Groups III, IV and V.
3.4. Serum Protein Carbonyl Levels. The serum protein
carbonyl levels in the ﬁve groups at 8 weeks are given in
Table 2. Serum protein carbonyl level in Group I was 1.34
± 0.25. The CsA and cholesterol diet increased the serum
protein carbonyl levels by 5.75- and 3.92-fold, respectively.
The levels in Group IV increased 11.33-fold as compared
with Group I while the levels were 2- and 2.9-fold higher
as compared with Groups II and III respectively. The serum
protein carbonyl levels were 38.8% lower as compared to
Group IV.
3.5. Histological Eﬀects
3.5.1. Extent of Atherosclerotic Plaque. Representative pho-
tographs of the atherosclerotic changes in the intimal surface
of the aortas from the ﬁve groups are shown in Figure 3
and the results are summarized in Table 2. There were no
atherosclerotic changes in the intimal surface of the aortas
in Groups I and II. Signiﬁcant areas of the intimal surfaces of
Groups III (45 ± 11%), IV (38 ± 4%) and V (18 ± 8%) were
covered with atherosclerotic plaques. TQ administration
(Group V) reduced the development of cholesterol + CsA-
induced atherosclerosis by 52%.
3.5.2. Microscopic Changes in the Aortic Segments. Histo-
logical examination of all animals in each group was ﬁrst
performed. Representative photographs of the histological
sections of the aorta stained with the H&E stain and Ver-
hoeﬀ’s elastic stain from the ﬁve groups were photographed
and are shown in Figures 4, 5,a n d6. In the control
group (Group I), specimens showed normal arterial wall
structure with no atherosclerotic changes. Administration of
CsA alone in Group II had no eﬀect on the atherosclerosis
parameters tested. InGroup III moderate (30–60%) to severe
(≥60%) atherosclerotic lesions was obvious. Administration
of CsA with the high-cholesterol diet in Group IV disclosed
severe diﬀuse atherosclerosis involving >85% of the arterial
wall and, in addition, smooth muscle cells proliferation
in the intima. Co-administration of TQ to CsA and the
high-cholesterol diet attenuated the vascular injury to only
minimal focal areas of atherosclerosis involving <20% of the
arterial wall. In addition there was no evidence of smooth
muscle cells proliferation.6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Representative photographs of the microscopic changes from the ﬁve groups stained with H&E stain. Note the normal arterial
wall structure in Group I, the increased intimal thickness in Group III that involves a large portion of the aortic circumference and almost
the whole circumference in Group IV. Also note the very small atheroma in Group V (magniﬁcation, 4x).
3.5.3. Changes in the Intimal and Medial Thickness in
the Aortic Segments. Three parameters were compared; the
intimal and medial thickness of the aortic specimens as
well as the intimal/medial ratio. The results are summarized
in Table 2. The intimal and medial cross-sectional areas
and the values of intima/media ratio in Group I were
7.6 ± 1.5 ×103 μm2, 52.3 ± 9.7 × 103 μm2 and 0.15 ±
0.01, respectively. CsA alone did not exert any signiﬁcant
eﬀect. In Group III, the intimal cross-sectional area and the
intima/media ratio values were increased 4.3- and 3.5-fold,
respectively, compared to those in Group I. Administration
of CsA to the high-cholesterol diet, in Group IV, signiﬁcantly
increased the intimal and medial cross-sectional areas and
the intima/media ratio 1.8, 1.4 and 1.3 times, respectively,
compared to that in Group III. Adding TQ in Group V to
both CsA- and cholesterol-rich diet decreased the intimal
cross-sectional area and the intima/media ratio values by 73
and 72%, respectively, compared to that in Group III.
3.5.4. Changes in the IEL and EEL in the Aortic Segments
with Verhoeﬀ’s Elastic Stain. Administration of CsA only in
Group II had no eﬀect. The high-cholesterol diet adminis-
t r a t i o ni nG r o u pI I Ip r o d u c e dd i ﬀuse damage to the IEL at
the sites of the atherosclerotic changes. Combining CsA to
the high-cholesterol diet disclosed diﬀuse damage to the IEL.
Co-administrationofTQtotheCsAandthehigh-cholesterol
diet reduced the damage to minimal focal areas of disruption
in the IEL.
4. Discussion
Thisstudyhighlightscertainpointsfordiscussion;ﬁrst,there
was no signiﬁcant diﬀerence in the body weight gain among
the studied groups (data not shown) indicating that the
various interventions did not aﬀect the body weight.
Second, our results corroborate similar eﬀects of the
high-cholesterol diet on the lipid proﬁle as reported in
previous studies [19, 20].
This study demonstrates some of the biological eﬀects
of clinical relevance, on CsA toxicity. First, CsA at the dose
used did not aﬀect lipid levels and thus its eﬀect on the
bioc hemicalc hangesandtissuedamageasr eport edinG r oup
II are not compounded by changes in serum lipid levels.
Among these biological eﬀects this study corroborates the
increased oxidative state after CsA administration. This was
well manifested by an increase in both serum MDA and
protein carbonyl levels by 1.4- and 5.8-fold, respectively,
when compared to the control group. In addition, CsA
increased the aortic MDA level 1.9-fold, but this level of
enhanced ROS activity was not high enough to induce
atherosclerosis. When CsA action was compared to that
induced by the high cholesterol diet the results demonstrated
a much higher level of oxidative stress induced by the
high cholesterol diet. The combination of CsA and high
cholesterol diet exerted a synergistic eﬀect on oxidative state
as manifested by an increase in serum MDA and protein
carbonyl as well as the aortic tissue MDA levels by 9.2-, 2-
and3.9-fold,respectively,whencomparedtothatinGroupIIEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Representative photographs of the microscopic changes from the ﬁve groups stained with Verhoeﬀ’s elastic stain with
magniﬁcation 10 and 20x. Note: (i) the normal arterial wall structure in Group I; (ii) the moderate to sever atherosclerosis in Group III
that involves a large portion of the aortic circumference; (iii) severe atherosclerosis in Group IV and the smooth muscle cells proliferation
in the intima; (iv) also note the very small atheroma in Group V and the absence of smooth muscle cells proliferation in the intima. Mild ≤
30%, moderate = 30–60%, severe ≥ 60%.
(CsAgroup)orwhencomparedtothehighcholesterolgroup
(1.3-, 2.9- and 2.3-fold, resp.).
Thus, the results proof the synergistic eﬀect of CsA
and high cholesterol diet on increasing oxidative stress.
Other studies corroborated the deleterious combination of
hyperlipidemia and CsA on atherosclerosis [21].
We have recently demonstrated that TQ inhibits the
formation of atherosclerotic plaque in this model by 50%
[12]. In this current study, the addition of CsA further
enhanced the protective eﬀect of TQ in the same model by
80%. Taken together, the results raise the intriguing appeal
that while TQ may abolish some of the deleterious eﬀects
of combined administration of CsA and hyperlipidemia, TQ
spares also or even unmasks some of the desirable eﬀects
of CsA such as the inhibition of atherosclerosis. The anti-
atherogenic eﬀect of CsA when used in combination with
TQ is both intriguing and may have signiﬁcant clinical
relevance. First, there is a plethora of evidence indicating a
role for the immune system in the development of vascular
disease. Thus, suppression of cell-mediated immunity by
CsA induced inhibition of T-lymphocytes [4, 22–24].
In this study, we used other parameters to assess the
developmentofatherosclerosis;theintimalandmedialcross-
sectional areas and the intima/media ratio. These parameters
were not tested in previous studies [4, 7]. A main ﬁnding of
this work was the beneﬁcial eﬀect of TQ on atherogenesis
parameters. First, it inhibited markers of oxidative stress
which included a decrease in the aortic tissue MDA content
by 84%. Another striking ﬁnding of our work is the eﬀect
of TQ in this model. TQ in Group V reduced the extent
of atherosclerosis by half and induced ∼75% reductions in
the intimal cross-sectional area and the intima/media ratio
as compared to CsA and the high cholesterol diet in Group
IV. Thus, these ﬁndings establish the useful eﬀect of TQ to
attenuate atherogenesis induced by hyperlipidemia which is
aggravated by CsA.
Our results diﬀer from those obtained by Drew and
Tipping who studied the eﬀect of CsA on a rabbit model
similar to ours [6]. They used 1% cholesterol diet for 4 weeks
to induce atherosclerosis in New Zealand white rabbits. CsA
was given at a dose of 16mgkg−1 of body weight IM every
second day for 4 weeks. In their study they reported that
CsA reduced the atherosclerotic plaques development in the
aortic arch, the thoracic and abdominal aorta by 55, 68
and 86%, respectively. It also reduced the cross-sectional
plaque area in the aortic arch by 55%. They attributed these
eﬀects to the anti-inﬂammatory eﬀects of CsA through the
preventionofT-cellsrecruitmentandreductionoffoamcells
accumulation in the atherosclerotic plaques. It is possible
that diﬀerences between our results and theirs might be8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Hypothetical diagram to present the beneﬁcial eﬀect of
thymoquinone.
explained by the lower dose and the shorter duration they
used. This explanation is corroborated with the results of
Roselaar and co-workers whodescribed an atherogenic eﬀect
of a larger dose CsA in the same animal model [4]. This
group induced atherosclerosis by 0.5% cholesterol diet and
gave CsA at a higher dose (20gkg−1 subcutaneously daily for
the ﬁrst week, and then twice weekly) for a longer duration
(12 weeks). They reported that CsA increased the extent of
atherosclerosis in the aortic arch and the thoracic aorta by
1.25- and 1.7-fold, respectively, as compared to the high-
c h o l e s t e r o ld i e ta l o n e .F r o mw h a ti ss a i db e f o r ew ep o s t u l a t e
that the eﬀect of CsA on the extent of atherosclerotic
plaques in cholesterol-fed animal models may depend on the
durationandtheCsAdose.Whenitisgiveninalowdoseand
forashortduration,CsAmayexertananti-atherogeniceﬀect
while, a further increase in the duration and dose induces
atherogenesis.
Clinical relevance of these ﬁnding as shown in Figure 7
include the possible therapeutic use of TQ in hyperlipidemic
patients on CsA therapy. Thus further controlled studies in
humans are suggested.
4.1. Limitations. Caution should be exercised to interpret
our results. We did not measure the oxidized LDL-C levels.
Oxidation of LDL-C molecules has been recognized as a
majoratherogenicfactorinpost-transplantpatients[25]and
is considered a key factor in the biological processes that
trigger and accelerate atherosclerosis [26]. Furthermore, we
neither measured tissue CsA levels nor tested the eﬀect of
varying CsA dosing in our model. Currently experiments are
performed to address these limitations and to delineate the
underlying mechanisms of the beneﬁcial eﬀects observed in
this descriptive study.
5. Conclusion
Enhanced oxidative stress is blamed for both hyperlipi-
demia and CsA. In reality, most patients on CsA are also
hyperlipemic. Therefore, the contribution of CsA versus
hyperlipidemia-induced damage is diﬃcult to dissect. Sim-
ilarly, in rabbits, hyperlipidemia has been reliably shown
to cause tissue injury due to enhanced oxidative stress.
Therefore,weraisedtheintriguingquestiontodeterminethe
relevanceofCsAtovascularinjuryinthepresenceorabsence
of hyperlipidemia.
CsA administration alone induced oxidative stress but
did not induce signiﬁcant eﬀect on the serum lipids or
the development of atherosclerosis. However, the high-
cholesterol diet induced a signiﬁcant increase in parameters
of oxidative stress as well as serum levels of TC, TG, LDL-
C, HDL-C, the TC/HDL-C ratio. In addition, it markedly
enhanced atherogenesis. Thirdly, the addition of CsA to high
cholesterol diet led to a further ampliﬁcation in the oxidative
stress and, thus, severe atherogenesis. A main ﬁnding of
this study is that TQ signiﬁcantly attenuated aortic MDA
levels and atherosclerosis in the presence of the deleterious
combination of CsA and hyperlipidemia.
This study suggests TQ as a potential agent to protect
against the deleterious eﬀe c to fc o m b i n e dC s Aa n dh y p e r -
lipidemia on atherosclerosis.
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